Wall Street is positive on Aridis Pharmaceuticals Inc (ARDS). On average, analysts give Aridis Pharmaceuticals Inc a Strong Buy rating. The average price target is $17, which means analysts expect the stock to climb by 226.30% over the next twelve months.
That average ranking earns Aridis Pharmaceuticals Inc an Analyst Rating of 75, which is better than 75% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating ARDS a Strong Buy today. Find out what this means to you and get the rest of the rankings on ARDS!
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Aridis Pharmaceuticals Inc Stock Today?
Aridis Pharmaceuticals Inc (ARDS) stock is trading at $5.21 as of 9:45 AM on Tuesday, Jul 20, a gain of $0.20, or 4.1% from the previous closing price of $5.00. The stock has traded between $5.17 and $5.34 so far today. Volume today is low. So far 21,434 shares have traded compared to average volume of 48,435 shares.
Click Here to get the full Stock Report for Aridis Pharmaceuticals Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
